Enterome lands Series D funding
Paris and Cambridge, Massachusetts-based Enterome, a biotech company focused on treating microbiome-associated diseases with a focus on inflammatory bowel diseases and immuno-oncology indications, has secured 32 million euros in Series D funding. The investors were Seventure, Health for Life Capital, LundbeckFonden Ventures, Omnes Capital, Nestlé Health Science, Principia SGR and Bristol-Myers Squibb.
4 January 2018•6 mins read
